GSK573719 125mcg

DRUG2 trials

Sponsors

GlaxoSmithKline

Conditions

Pulmonary Disease, Chronic Obstructive

Phase 2

28-day Repeat Dose Study of GSK573719

CompletedNCT01030965

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2009-12-15End: 2010-07-04Updated: 2018-03-09

Phase 3

A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD

CompletedNCT01313637

GlaxoSmithKlinePulmonary Disease, Chronic Obstructive

Start: 2011-03-01End: 2012-04-19Updated: 2018-01-29

Related Papers

Impact of prior and concurrent medication on exacerbation risk with long-acting bronchodilators in chronic obstructive pulmonary disease: a post hoc analysis.

2019-03-269 citations

A meta-analysis of four randomized clinical trials to confirm the reliability and responsiveness of the Shortness of Breath with Daily Activities (SOBDA) questionnaire in chronic obstructive pulmonary disease.

2015-10-315 citations

Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study.

2014-05-01122 citations